Skip to main content

The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].

Publication ,  Conference
Sharifi, N; Azad, A; Patel, M; Hearn, JWD; Wozniak, M; Zohren, F; Sugg, J; Haas, GP; Stenzl, A; Armstrong, AJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharifi, N., Azad, A., Patel, M., Hearn, J. W. D., Wozniak, M., Zohren, F., … Armstrong, A. J. (2022). The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Sharifi, Nima, Arun Azad, Mona Patel, Jason W. D. Hearn, Michele Wozniak, Fabian Zohren, Jennifer Sugg, Gabriel P. Haas, Arnulf Stenzl, and Andrew J. Armstrong. “The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences